Cargando…

Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the etiology of type 2 diabetes

Type 2 diabetes (T2D) is a heritable metabolic disorder. While population studies have identified hundreds of common genetic variants associated with T2D, the role of rare (frequency < 0.1%) protein-coding variation is less clear. We performed exome sequence analysis in 418,436 (n = 32,374 T2D ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Eugene J., Kentistou, Katherine A., Stankovic, Stasa, Lockhart, Samuel, Wheeler, Eleanor, Day, Felix R., Kerrison, Nicola D., Wareham, Nicholas J., Langenberg, Claudia, O'Rahilly, Stephen, Ong, Ken K., Perry, John R.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750938/
https://www.ncbi.nlm.nih.gov/pubmed/36530175
http://dx.doi.org/10.1016/j.xgen.2022.100208
Descripción
Sumario:Type 2 diabetes (T2D) is a heritable metabolic disorder. While population studies have identified hundreds of common genetic variants associated with T2D, the role of rare (frequency < 0.1%) protein-coding variation is less clear. We performed exome sequence analysis in 418,436 (n = 32,374 T2D cases) individuals in the UK Biobank. We identified previously reported genes (GCK, GIGYF1, HNF1A) in addition to missense variants in ZEB2 (n = 31 carriers; odds ratio [OR] = 5.5 [95% confidence interval = 2.5–12.0]; p = 6.4 × 10(−7)), MLXIPL (n = 245; OR = 2.3 [1.6–3.2]; p = 3.2 × 10(−7)), and IGF1R (n = 394; OR = 2.4 [1.8–3.2]; p = 1.3 × 10(−10)). Carriers of damaging missense variants within IGF1R were also shorter (−2.2 cm [−1.8 to –2.7]; p = 1.2 × 10(−19)) and had higher circulating insulin-like growth factor-1 (IGF-1) protein levels (2.3 nmol/L [1.7–2.9]; p = 2.8 × 10(−14)), indicating relative IGF-1 resistance. A likely causal role of IGF-1 resistance was supported by Mendelian randomization analyses using common variants. These results increase understanding of the genetic architecture of T2D and highlight the growth hormone/IGF-1 axis as a potential therapeutic target.